M, trading at $0.29 on the NASDAQ. This SniperIQ fundamentals page covers Ensysce Biosciences's valuation, profitability (net margin -810.6%), revenue ($5M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
M
Net Margin-810.6%
Revenue (FY25)$5M

Full research coverage

Frequently Asked Questions

What is Ensysce Biosciences's market cap?

Ensysce Biosciences (ENSC) has a market capitalization of approximately

M, trading at $0.29 on the NASDAQ. Market cap moves with the live share price.

How profitable is Ensysce Biosciences?

Ensysce Biosciences runs a net profit margin of -810.6%, a gross margin of -103.7%, and an operating margin of -813.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Ensysce Biosciences generate?

Ensysce Biosciences reported revenue of $5M for fiscal year 2025, with net income of -

Does Ensysce Biosciences pay a dividend?

Ensysce Biosciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Ensysce Biosciences financially healthy?

Ensysce Biosciences carries a debt-to-equity ratio of -0.72x and a current ratio of 0.71x, with a market beta of 0.79. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Ensysce Biosciences a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ensysce Biosciences (ENSC) the key facts are: market cap

M, revenue $5M, 52-week range 0.23-2.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Ensysce Biosciences's full fundamentals live

Get Ensysce Biosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.